AstraZeneca to pay for rights to two drugs from Nektar
스크롤 이동 상태바
AstraZeneca to pay for rights to two drugs from Nektar
기자명
메디칼라이터팀
입력 2009.09.23 00:00
수정 2009.09.23 09:50
댓글 0
AstraZeneca will pay $125 million upfront for the rights to Nektar"s experimental drugs, NKTR-118 which treats constipation caused by opioid pain drugs, and NKTR-119 which combines NKTR-118 with opioid pain drugs to create a painkiller that doesn"t cause constipation. AstraZeneca will handle the late-stage clinical trials for NKTR-118, as well as manufacturing and marketing while the drug, NKTR-119 is still in early development.